The FDA is seeking comments on a draft document entitled “Guidance for Industry: Somatic Cell Therapy for Cardiac Disease,” which provides sponsors of cellular therapies for the treatment of cardiac disease with recommendations on the design of preclinical and clinical studies, and information that should be submitted about the product delivery system. It also provides recommendations on the chemistry, manufacturing, and controls information to include in an investigational new drug application for cardiac cellular therapy. Comments will be accepted until July 1, 2009.